Skip to main content
main-content

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in oncology

Adis Journal Club

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

This study couples pharmacokinetic modeling of initial doses used in the first human study of the B-cell maturation antigen × CD3 bispecific antibody teclistamab with data from a patient-derived ex vivo cytotoxicity assay to predict the efficacious therapeutic dosing range of teclistamab. 
The featured article was funded by Janssen Research & Development.

Panel discussion

An overview of the detection and treatment of ROS1 fusion-positive NSCLC

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

New additions to the Adis Journal Club – November update

Browse November's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

On-demand webcast

Advances in prostate cancer treatment and prognosis

This independent medical education meeting has been funded by Astellas.

Medical education

Virtual simulations

This activity is intended for US healthcare providers and was made possible by educational funding provided by Astellas Pharma.

IN FOCUS | Lung & thoracic cancers

DNA mutation

28-10-2022 | Non-small-cell lung cancer | News

Real-world study adds support for osimertinib for uncommon EGFR mutations

Osimertinib elicits high rates of systemic and intracranial response in people with advanced non-small-cell lung cancer harboring uncommon EGFR mutations, say the authors of the real-world UNICORN study.

IN FOCUS | Breast cancer

Mature woman resting on sofa and having hot flash

18-11-2022 | Breast cancer | News

Novel nonhormonal agent shows promise for hot flashes, night sweats in patients with breast cancer

The oral nonhormonal agent Q-122 appears to be an efficacious and well tolerated option for the control of vasomotor symptoms in women with breast cancer receiving adjuvant endocrine therapy, suggest phase 2 trial data.

IN FOCUS | Genitourinary cancers

Syringe, vials and pills

14-11-2022 | Renal cell carcinoma | News

Second-line metastatic RCC outcomes similar regardless of first-line immunotherapy combo partner

Among patients with metastatic clear cell renal cell carcinoma, the outcomes of second-line treatment are similar irrespective of whether they received dual immunotherapy or IO plus a tyrosine kinase inhibitor in the first line, indicates a chart review.

IN FOCUS | COVID-19 & cancer

Positive test result by using rapid test device for COVID-19

07-11-2022 | COVID-19 | News

Anticancer therapy tied to worse COVID-19 outcomes in people receiving immunosuppressive agents

People with cancer receiving immunotherapy or other anticancer treatments are at increased risk for adverse COVID-19 outcomes if they are also receiving immunosuppressive therapy, suggests a registry-based cohort study.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox